Parabilis Raises $670 Million in Largest-Ever Biotech IPO

Parabilis has raised $670 million in its initial public offering, a figure BioPharma Dive reports as a record for a biotech IPO.

The deal marks the largest debut the sector has seen, according to the trade publication, which broke the news of the raise. The $670 million haul underscores that investors remain willing to write sizable checks for biotechnology companies despite a market that has punished many newly public firms in recent years.

The size of the offering places Parabilis at the top of the biotech IPO rankings. Prior biotech debuts have occasionally crossed into the hundreds of millions, but none, per BioPharma Dive's reporting, has matched this figure.

Details of the pricing — the number of shares sold, the price per share, and the lead underwriters — were not disclosed in the report. The company's pipeline and clinical-stage assets also remain to be detailed in follow-on coverage.

What is clear is the headline number. A $670 million IPO in biotechnology signals that large-scale public-market appetite for the sector has not disappeared, and it sets a fresh benchmark against which every subsequent biotech listing will now be measured.